COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma
10th July 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally